REG - Novacyt S.A. - Directorate Change

Novacyt SAAnnouncement

26/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240926:nRSZ6681Fa&default-theme=true

RNS Number : 6681F  Novacyt S.A.  26 September 2024

 

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

 

Directorate change

Dr John Brown CBE appointed as Chairman

 

Paris, France, and Eastleigh and Manchester, UK - 26 September 2024 - Novacyt
S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular
diagnostics company with a broad portfolio of integrated technologies and
services, announces the appointment of Dr John Brown CBE as Chairman effective
from 1 October 2024. Dr Brown was appointed Non-executive Director of Novacyt
in September 2023 following the acquisition of Yourgene Health and will
succeed James Wakefield, who is retiring from the Board having been Chairman
since before the company joined AIM in 2017.

 

Dr Brown has over 38 years industry experience, which includes significant
capital markets and board experience in the healthcare and life sciences
sector. He is currently Chairman of Laverock Therapeutics Ltd and Calcivis
Ltd, and until recently was Chairman of Synpromics Ltd, BioCity Group and the
Cell and Gene Therapy Catapult. Previously, he was Chairman of Kyowa Kirin
International plc, BTG plc, Axis-Shield plc, Touch Bionics Ltd and CXR
Biosciences Ltd and Senior Non-Executive Director of Quantum Pharma plc. Dr
Brown was appointed to the Board of Yourgene Health in July 2019 as a
Non-executive Director and became Chairman in April 2022.

 

 

Dr John Brown CBE

Chairman of Novacyt S.A.

 

Lyn Rees, CEO of Novacyt, commented: "It is a pleasure to have John stepping
into the role of Chairman at Novacyt.  John has a proven track record of
successfully building life sciences companies and his wealth of knowledge in
capital markets and the life sciences sector will be important as we look to
execute the strategic plan of the combined business.

 

"I would like to thank James for his contribution and leadership of Novacyt,
especially navigating the business through the pandemic and its aftereffects.
Under James' tenure, the business has made a series of successful
acquisitions, including Primerdesign and more recently Yourgene Health. James
leaves the business in a strong financial position, with significant cash
resources and a broad portfolio of molecular diagnostics products and
services."

 

Dr John Brown, Incoming Chairman said: "I am delighted to be appointed
Chairman of Novacyt. The Group has a strong and diverse portfolio of
differentiated molecular diagnostic products, established sales channels and a
world-class team of experts. I look forward to continuing to work with Lyn and
the rest of the Board as we drive the business through the next stage of
development."

 

This announcement contains inside information for the purposes of Article 7 of
Regulation (EU) 596/2014.

 

Contacts

 

 Novacyt SA                                                              https://novacyt.com/investors (https://novacyt.com/investors/)
 Lyn Rees, Chief Executive Officer                                        Via Walbrook PR
 Steve Gibson, Chief Financial Officer

 SP Angel Corporate Finance LLP (Nominated Adviser and Broker)                                             +44 (0)20 3470 0470
 Matthew Johnson / Charlie Bouverat (Corporate Finance)

 Vadim Alexandre / Rob Rees (Corporate Broking)

 Deutsche Numis (Joint Broker)                                                                             +44 (0)20 7260 1000
 Freddie Barnfield / Duncan Monteith / Michael Palser

 Allegra Finance (French Listing Sponsor)       +33 (1) 42 22 10 10

                                             r.durgetto@allegrafinance.com (mailto:r.durgetto@allegrafinance.com) /
 Rémi Durgetto / Yannick Petit                 y.petit@allegrafinance.com

 Walbrook PR (Financial PR & IR)                                         +44 (0)20 7933 8780 or novacyt@walbrookpr.com

 Stephanie Cuthbert / Paul McManus /                                     +44 (0)7796 794 663 / +44 (0)7980 541 893

 Phillip Marriage / Alice Woodings                                        +44 (0)7867 984 082 / +44 (0)7407 804 654

 

About Novacyt Group (www.novacyt.com)

Novacyt is an international molecular diagnostics company providing a broad
portfolio of integrated technologies and services, primarily focused on the
delivery of genomic medicine. The Company develops, manufactures, and
commercialises a range of molecular assays and instrumentation to deliver
workflows and services that enable seamless end-to-end solutions from sample
to result across multiple sectors including human health, animal health and
environmental.

 

The Company is divided into three business segments:

 

 Clinical             Broad portfolio of human clinical in vitro diagnostic products, workflows and
                      services focused on three therapeutic areas:

                      ·    Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy
                      tests

                      ·    Precision Medicine: DPYD genotyping assay

                      ·    Infectious Diseases: Winterplex, multiplex winter respiratory PCR
                      panel
 Instrumentation      Portfolio of next generation size selection DNA sample preparation platforms
                      and rapid PCR machines, including:

                      ·    Ranger® Technology: automated DNA sample preparation and target
                      enrichment technology

                      ·    MyGo: real-time quantitative PCR (qPCR) instruments

 Research Use Only    Range of services for the life sciences industry:

                      ·    Design, manufacture, and supply of high-performance qPCR assays and
                      workflows for use in human health, agriculture, veterinary and environmental,
                      to support global health organisations and the research industry

                      ·    Pharmaceutical research services: whole genome sequencing (WGS) /
                      whole exome sequencing (WES)

 

Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the
UK (in Stokesley, Eastleigh and Manchester), Singapore, the US and Canada and
has a commercial presence in over 65 countries. The Company is listed on the
London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange
Euronext Growth ("ALNOV").

 

For more information, please refer to the website: www.novacyt.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOALAMJTMTITBTI